The US FTC charges two pharmaceutical companies for preventing competition in the national market for oxymorphone (Endo / Impax)

FTC Again Charges Endo and Impax with Illegally Preventing Competition in U.S. Market for Oxymorphone ER* The FTC is suing Endo Pharmaceuticals Inc., Endo International plc, Impax Laboratories, LLC, and Impax’s owner, Amneal Pharmaceuticals, Inc., alleging that a 2017 agreement between Endo and Impax violated the antitrust laws by eliminating competition in the market for oxymorphone ER. The FTC sued Endo and Impax in January 2017 for engaging in similar anticompetitive conduct concerning the same drug product. “The agreement between Endo and Impax has eliminated the incentive for competition, which

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

US Federal Trade Commission, The US FTC charges two pharmaceutical companies for preventing competition in the national market for oxymorphone (Endo / Impax), 25 January 2021, e-Competitions Pay-for-delay agreements, Art. N° 98900

Visites 193

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues